Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

A Multicenter Prospective Observational Study of Triple Therapy with Rabeprazole, Amoxicillin and Metronidazole for Helicobacter pylori in Japan

(2014) Katsuya Sugizaki et al.   INTERNAL MEDICINE

Changes in the first lineHelicobacter pylorieradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (TokyoHelicobacter pyloristudy group)

(2014) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

(2013) L. Gatta et al.   BMJ-British Medical Journal

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

A new approach for elimination of gastric cancer deaths in Japan

(2012) Masahiro Asaka   INTERNATIONAL JOURNAL OF CANCER

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Helicobacter pyloriInfection

(2010) Kenneth E.L. McColl   NEW ENGLAND JOURNAL OF MEDICINE

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology